Stock Market Reviews

AUPH (Aurinia Pharmaceuticals Inc.) News

Get the latest news, insights, and market updates on AUPH (Aurinia Pharmaceuticals Inc.). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Can Aurinia (AUPH) Run Higher on Rising Earnings Estimates?
  Aurinia Pharmaceuticals (AUPH) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
  Nov 7, 2025 - $AUPH
• Aurinia Pharmaceuticals (AUPH) Profitability Milestone Reinforces Bullish Growth and Valuation Narratives
  Aurinia Pharmaceuticals (AUPH) has swung into profitability over the past year, with earnings climbing at an impressive 43.8% per year on average for the past five years. Investors have watched as forecasts point to ongoing momentum, with revenue expected to rise 12.5% per year, outpacing the US market, and earnings projected to grow 17.1% per year. Margins have expanded alongside the company’s shift to profitability, highlighting a period of strong operational execution and improved...
  Nov 5, 2025 - $AUPH
• Aurinia: Q3 Earnings Snapshot
  EDMONTON, Alberta (AP) — Aurinia Pharmaceuticals Inc. AUPH) on Tuesday reported third-quarter earnings of $31.6 million. On a per-share basis, the Edmonton, Alberta-based company said it had profit of 23 cents.
  Nov 4, 2025 - $AUPH
• Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2025 and Provides Update on Recent Business Progress
  ROCKVILLE, Md. & EDMONTON, Alberta, November 04, 2025--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and nine months ended September 30, 2025, and provided an update on recent business progress.
  Nov 4, 2025 - $AUPH
• Aurinia Pharmaceuticals Inc (AUPH) Q3 2025 Earnings Call Highlights: Strong Lupkynis Sales and ...
  Aurinia Pharmaceuticals Inc (AUPH) reports significant growth in Lupkynis sales and raises its 2025 sales guidance, while navigating legal and regulatory hurdles.
  Nov 4, 2025 - $AUPH
• Aurinia Pharmaceuticals (AUPH) Surpasses Q3 Earnings and Revenue Estimates
  Aurinia (AUPH) delivered earnings and revenue surprises of +43.75% and +7.31%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 4, 2025 - $AUPH
• Tidmarsh resigns from CDER; Kenvue to sell to Kimberly-Clark
  George Tidmarsh’s short run directing the agency’s principal drug review office reportedly ended in controversy. Elsewhere, Moderna advanced a T-cell engager and Lilly expanded a production push for its GLP-1 pill.
  Nov 3, 2025 - $AUPH
• Sector Update: Health Care Stocks Decline in Afternoon Trading
  Health care stocks declined Monday afternoon, with the NYSE Health Care Index shedding 0.3% and the
  Nov 3, 2025 - $AUPH
• Update: Aurinia Pharmaceuticals Reportedly Files Lawsuit Against US FDA Official
  (Updates with US Department of Health and Human Services' comments in the fifth and sixth paragraphs
  Nov 3, 2025 - $AUPH
• Aurinia Pharmaceuticals Reportedly Files Lawsuit Against US FDA Official
  Aurinia Pharmaceuticals (AUPH) has filed a lawsuit against US Food and Drug Administration drug divi
  Nov 3, 2025 - $AUPH